Home Development of a disease diagnostic model to predict the occurrence of central precocious puberty of female
Article Open Access

Development of a disease diagnostic model to predict the occurrence of central precocious puberty of female

  • Manman Zhao , Guoshuang Feng , Bingyan Cao , Yannan Zheng and Chun-Xiu Gong ORCID logo EMAIL logo
Published/Copyright: January 16, 2025

Abstract

Objectives

To develop a clinical model for predicting the occurrence of Central Precocious Puberty based on the breast development outcomes in chinese girls.

Methods

This is a retrospective study, which included a total of 1,001 girls aged 6–9 years old who visited the outpatient clinic of Beijing Children’s Hospital from January 2017 to October 2022 for “breast development”. Participants were categorized into pubertal development (PD) cohort and simple premature breast development (PT) according to the criteria, and information was collected and tested for relevant indicators. After dealing with missing data, logistic regression, LASSO regression and random forest were used to screen the variables, and support vector machine models were built with SMOTE oversampling and ten-fold cross-validation to assess the effectiveness of the models in the training and validation sets.

Results

A total of 1,001 girls were included in the analysis, of whom 369 (36.9 %) were diagnosed with PD and 632 (63.1 %) with PT. Body mass index (BMI), bone age (BA), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), uterine diameter, and ovary volume were identified as the final predictor variables by three variable screening methods. The AUC of the constructed disease diagnostic model was 0.9457 in the developmental cohort and 0.8357 in the external validation group, and sensitivity analyses revealed that the performance of the constructed models with different variable selection strategies was similar.

Conclusions

A disease diagnostic model was developed that may help predict a girl’s risk of diagnosing central precocious puberty.

Introduction

The onset of early adolescence in girls, marked by the appearance of secondary sexual traits before reaching 7.5 years of age, is termed premature puberty [1]. This condition can be divided into central premature adolescence (CPP), peripheral premature adolescence, and incomplete premature adolescence. CPP is triggered by the activation of the hypothalamic–pituitary–gonadal (HPG) axis. Idiopathic central precocious puberty (ICPP), which has an unknown cause, is the most common cause of precocious puberty in girls [2]. Female early puberty (EP) is characterized by the emergence of secondary sexual characteristics before the age of 9 [3], 4]. Collectively, ICPP and EP are referred to as pubertal development (PD). Premature thelarche (PT), considered a variant of premature puberty, is generally benign and does not necessitate treatment [5]. However, early onset of CPP or accelerated pubertal advancement may result in premature menarche in females, potentially stunting their growth and causing psychosocial issues, thus requiring timely diagnosis and management. Typically, girls with central premature puberty exhibit breast development as the initial sign. Hence, early identification of genuine premature puberty is crucial.

Currently, the diagnosis of CPP increasingly emphasizes the role of basal sex hormones, but GnRH provocation test is still required when there is a high index of suspicion. The non-physiological nature of the GnRH stimulation test does not reflect the true level of gonadal development and requires multiple blood draws, causing some inconvenience to the patients. Therefore, clinicians are committed to finding more reliable, feasible, and convenient indicators for the diagnosis of CPP.

We aimed to construct a disease diagnostic model based on the breast development outcomes in Chinese girls to identify girls with true precocious puberty in a timely manner without overdiagnosis.

Materials and methods

Subjects and group stratification

This is a retrospective study. A total of 1,102 young girls, ranging from 6 to 9 years of age, who presented at the outpatient department of Beijing Children’s Hospital between January 2017 and October 2022 with the primary concern of “breast development,” were incorporated into the research sample. Comprehensive clinical information and the progress of follow-up were meticulously evaluated. The participants experiencing “breast development” underwent thorough examinations, including breast and pelvic ultrasounds, bone age assessments, and laboratory tests for hormones such as sex hormones and thyroid hormones. Following the monitoring period, the participants were divided into two distinct groups: the PD cohort and the PT cohort, with the diagnostic criteria for these outcome groups outlined as follows.

Due to the retrospective nature of the study, committees of Beijing Children’s Hospital waived the need of obtaining informed consent. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki. The study was approved by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University (No.2020-k-180).

Diagnostic criteria

The diagnostic benchmarks for PD with the manifestation of secondary sexual traits in females under the age of 9, are outlined in the 2022 Chinese clinical guidelines [1]. For the diagnosis of PT, the girl exhibited premature breast development before reaching 8 years of age, details of these criteria have been previously documented in my personal published work [2].

Observations

Each participant was thoroughly questioned regarding their health records followed by a comprehensive physical assessment, which involved measurements of height, weight, and calculation of body mass index (BMI). The BMI was derived using the standard equation [BMI (kg/m2)=weight (kg)/height2 (m2)]. The maturation of breast tissue was evaluated based on the Tanner scale and tracked at quarterly intervals until the age of 9. Concentrations of sex hormones such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone were assayed via immunochemiluminescence at three-month intervals. Pelvic imaging via ultrasound was conducted quarterly by a skilled endocrine sonographer. The assessment of bone age (BA) was carried out every half-year using the G-P technique by a consistent pediatric endocrinologist throughout the study.

Potential predictive variables

Potential predictive variables included the following patient characteristics: anthropometry, clinical signs and symptoms, laboratory findings, and imaging results. Anthropometry variables included chronological age (CA), height, height SDS, weight, weight SDS, BMI and BMI SDS. Clinical signs and symptoms: Tanner staging of breast development. Laboratory findings included basal FSH, LH, and estradiol (E2). Imaging results included BA, uterine diameter, ovarian volume.

Variable selection and model construction

In the developmental cohort, 1,102 participants with breast development were incorporated into the variable selection phase and the subsequent model creation. As previously mentioned, a total of 14 factors were initialized into the variable selection mechanism. The strategy for processing missing data is to conduct multiple imputations using the mice package. Since the missing variables in this study are predominantly continuous variables, the predictive mean matching (ppm) method was selected for imputation.

The proportion of positive endings in the training set of this study was 36.9 %. To avoid building a prediction model in which the model gives higher weights to a larger proportion of the population, thus reducing the prediction effect on the positive samples, a relatively novel model training method was used in this study. First, the training set population was SMOTE oversampled to equalize the proportion of positive and negative samples. Then, variable selection and model training were carried out in the oversampled samples. This study uses support vector machine for modeling. To avoid overfitting when training the model, the study uses ten-fold cross-validation to train the model. At this point, the trained model has equal importance for positive and negative samples and there is no risk of overfitting. This model is applied to the original training and validation sets as the predictive effect of the model in the training and validation sets.

For variable selection, this study employed both logistic regression, LASSO regression, and random forest for variable screening. In logistic regression, variables with p<0.05 were selected. In LASSO regression, to select more streamlined variables and simplify the model, the study utilized a larger λ (λ 1se) as the criterion for variable selection. For the random forest model, the study selected variables within the top 50 % of the importance ranking. Eventually, the intersection and union of the variables screened by the three methods were taken. The SVM was fitted using the intersection of the variables screened by the three methods as the final prediction model, and the prediction effect was explored on the original training set and the validation set. In the sensitivity analysis, this study used the union of the selected variables of the three methods to fit the model and compared it with the previous model to verify the influence of the variable selection strategy on the results.

Assessment of predictive performance

The predictive performance of the model was assessed using sensitivity, specificity, accuracy and area under the receiver–operator characteristic curve (AUC).

Results

At the initial stage, a cohort of 1,102 females, ranging from 6 to 9 years of age, were enrolled. However, 90 of these participants did not complete the follow-up, and an additional 11 were dismissed due to specific medical conditions: four suffered from congenital adrenal hyperplasia (CAH), while seven had ovarian cysts. Consequently, the analysis was conducted on 1,001 individuals for whom follow-up data was available. Regarding the outcomes, the participants were divided into two groups: those who met the criteria for PD at any point throughout the follow-up period, and those who only qualified for a straightforward PT. Ultimately, 369 (36.9 %) were diagnosed with PD, whereas 632 (63.1 %) received a PT diagnosis. The diagnosis of PD was based on the concurrent fulfillment of five diagnostic criteria. The process of participant selection and recruitment is depicted in Figure 1.

Figure 1: 
Flowchart of participant screening and enrolment CAH, congenital adrenal hyperplasia; ICPP, idiopathic central precocious puberty; EP, early puberty; PD, pubertal development; PT, premature thelarche.
Figure 1:

Flowchart of participant screening and enrolment CAH, congenital adrenal hyperplasia; ICPP, idiopathic central precocious puberty; EP, early puberty; PD, pubertal development; PT, premature thelarche.

Characteristics of the development cohort

Overall, the mean (SD) age of patients in the cohort was 7.69 (0.74) years. The comparative analysis of the physical status of the children in the two groups revealed that the PD group had significantly higher height, weight, and BMI as compared with the PT group. Children in the PD group had advanced BA, sex hormone levels, and pelvic ultrasound parameters. Their anthropometrics and laboratory values are listed in Table 1.

Table 1:

Anthropometry and clinical characteristics among patients in the development cohort.

Characteristic Overall mean (sd) PT mean (sd) PD mean (sd) p-Value
No 1,001 632 369
Age, years 7.69 (0.74) 7.59 (0.71) 7.85 (0.76) <0.001
Height, cm 129.85 (7.25) 128.21 (6.58) 132.68 (7.48) <0.001
Height SDS 0.81 (1.09) 0.61 (1.05) 1.14 (1.07) <0.001
Weight, kg 28.06 (5.61) 27.07 (5.12) 29.74 (6.02) <0.001
Weight SDS 1.01 (1.29) 0.86 (1.28) 1.26 (1.28) <0.001
BMI, kg/m2 16.43 (2.62) 16.26 (2.82) 16.73 (2.22) 0.006
BMI SDS 0.58 (1.37) 0.51 (1.48) 0.70 (1.15) 0.039
BA, years 8.51 (1.40) 8.11 (1.31) 9.20 (1.28) <0.001
BA/CA 1.11 (0.16) 1.07 (0.15) 1.17 (0.15) <0.001
Basal LH, IU/L 0.45 (0.84) 0.14 (0.32) 0.98 (1.13) <0.001
Basal FSH, IU/L 3.47 (2.06) 2.78 (1.41) 4.65 (2.43) <0.001
E2, pg/mL 26.94 (18.71) 21.29 (13.89) 36.62 (21.72) <0.001
Uterine diameter, cm 3.74 (0.65) 3.54 (0.57) 4.08 (0.66) <0.001
Ovarian volume, mL 1.41 (0.51) 1.31 (0.48) 1.58 (0.50) <0.001
  1. PT, premature thelarche; PD, pubertal development; BMI, body mass index; BA, bone age; CA, chronological age; LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, estradiol.

Predictor selection

Table 2 presents the results of modeling the screening of important variables related to CPP using each of the three methods. The details of the variable screening process for the three methods can be found in the Supplementary Material. LASSO screened the largest number of variables, with a count of 9. Logistic regression screened a slightly smaller number of variables, totaling 8. Random forests screened the least number of variables, precisely six. The intersection of the results of the three methods led to the following predictors of CPP: BA, LH, FSH, E2, uterine diameter, and ovarian volume.

Table 2:

Predictor variables screened by three different models.

Variable Logistic LASSO Random forest
Age, years 1 0 0
Height SDS 0 1 0
BMI 1 1 0
BA 1 1 1
LH 1 1 1
FSH 1 1 1
E2 1 1 1
Uterine diameter 1 1 1
Ovarian volume 1 1 1
  1. BMI, body mass index; BA, bone age; CA, chronological age; LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, estradiol.

Frisch [6] introduced the “critical weight hypothesis” in the 1970s, suggesting that a particular level of body fat reserve is essential for the onset of normal reproductive activity. In line with this, our research team [2] observed that children diagnosed with CPP exhibited an average BMI of 17.0 kg/m2, which corresponds to the BMI of a normally developing girl at 10.5 years of age. Considering the vast population in China, incorporating BMI into the diagnostic model for the disease can help decrease the incidence of misdiagnosis to a certain degree.

So, the seven variables were included in the disease diagnostic model: BMI, BA, LH, FSH, E2, uterine diameter, and ovarian volume.

Construction of the disease diagnostic model

Based on the selected variables as mentioned above, this study employs 10 % cross-validation to construct a support vector machine model for the population following SMOTE oversampling. In this model, the radial basis function method is utilized. This method proves highly effective in handling nonlinear classification problems, as it can map data into a high-dimensional space to identify a more appropriate classification hyperplane.

The performance of CPP disease diagnostic model

When the developed model was applied to the development cohort, the corresponding prediction results are presented in Table 3. From the confusion matrix, regarding PT, the model correctly predicted 579 cases as PT and misclassified 53 cases as PD, with a total of 632 cases. For PD, the model misclassified 57 cases as PT and accurately predicted 312 cases as PD, amounting to 369 cases. The overall total sample size was 1,001 cases. The performance of the model was further evaluated using the relevant indexes. Its Accuracy was 0.8901, Sensitivity was 0.9104, Specificity was 0.8548, and AUC was 0.9457 (Figure 2), suggesting that the model performed well in differentiating between PT and PD.

Table 3:

Confusion matrix of the predicted results of the constructed model in development cohort.

Reference Total
PT PD
Prediction PT 579 53 632
PD 57 312 369
Total 636 365 1,001
  1. PT, premature thelarche; PD, pubertal development.

Figure 2: 
The receiver–operator characteristic (ROC) curve of CPP in girls with breast development was predicted using a model based on the variables included in the intersection set. CPP, central precocious puberty; ROC, receiver–operator characteristic; AUC, area under the receiver–operator characteristic curve.
Figure 2:

The receiver–operator characteristic (ROC) curve of CPP in girls with breast development was predicted using a model based on the variables included in the intersection set. CPP, central precocious puberty; ROC, receiver–operator characteristic; AUC, area under the receiver–operator characteristic curve.

Verification of the CPP disease diagnostic model

We assembled an external verification group comprising 226 young girls, ranging from 6 to 9 years of age, who were patients at either Luhe Hospital or the Pediatric Traditional Chinese Medicine Unit of Beijing Children’s Hospital. Within this group, 149 individuals (constituting 66 %) experienced premature isolated breast development, while 77 (accounting for 34 %) underwent precocious puberty. The characteristics of each variable are shown in Table 4.

Table 4:

Clinical characteristics of patients in validation cohorts.

Characteristic Overall mean (sd) PT mean (sd) PD mean (sd) p-Value
No 226 149 77
Age, years 7.50 (0.87) 7.33 (0.87) 7.84 (0.77) <0.001
Height, cm 128.95 (7.72) 127.46 (7.48) 131.84 (7.39) <0.001
Height SDS 0.86 (1.08) 0.79 (1.09) 0.99 (1.04) 0.202
Weight, kg 27.85 (5.60) 26.78 (4.82) 29.91 (6.39) <0.001
Weight SDS 1.11 (1.26) 1.01 (1.20) 1.30 (1.36) 0.104
BMI, kg/m2 16.61 (2.17) 16.38 (1.98) 17.05 (2.46) 0.028
BMI SDS 0.59 (1.10) 0.49 (1.01) 0.77 (1.23) 0.069
BA, years 8.39 (1.38) 8.08 (1.30) 9.00 (1.35) <0.001
BA/CA 1.12 (0.13) 1.10 (0.12) 1.15 (0.13) 0.005
Basal LH, IU/L 0.33 (0.60) 0.14 (0.28) 0.70 (0.84) <0.001
Basal FSH, IU/L 3.46 (1.77) 3.15 (1.54) 4.07 (2.03) <0.001
E2, pg/mL 24.65 (20.65) 18.66 (11.02) 36.25 (28.63) <0.001
Uterine diameter, cm 3.70 (0.71) 3.54 (0.65) 4.01 (0.71) <0.001
Ovarian volume, mL 1.44 (0.51) 1.36 (0.49) 1.61 (0.51) <0.001
  1. PT, premature thelarche; PD, pubertal development; BMI, body mass index; BA, bone age; CA, chronological age; LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, estradiol.

The results of applying the model to the external validation group are presented in Table 5. In the prediction results, within the PT population, the model correctly identified PT in 119 cases and incorrectly identified PD in 30 cases, with a total of 149 cases. For the PD population, there were 19 cases where the model incorrectly identified PT and 58 cases where it accurately identified PD, totaling 77 cases, and the total sample size was 226 cases. The performance of the model was further evaluated using the relevant indexes. Its Accuracy was 0.7832, Sensitivity was 0.8623, Specificity was 0.6591, and AUC was 0.8357 (Figure 2). This value is slightly lower than the AUC value in the development cohort, yet it still exhibits a relatively good diagnostic performance in the external validation group.

Table 5:

Confusion matrix of the predicted results of the constructed model in external verification group.

Reference Total
PT PD
Prediction PT 119 30 149
PD 19 58 77
Total 138 88 226
  1. PT, premature thelarche; PD, pubertal development.

Sensitivity analysis

To verify whether the variable strategy in this paper affects the model performance, a predictive model using the variables included in the union variables was employed in the sensitivity analysis. The performance of this model was tested in the development cohort and the external verification group, respectively, and then compared with that of the simplified model. It was found that the performances were close to each other see Supplementary Material SFigure 3.

Discussion

To date, there is an increasing emphasis on basal sex hormone levels for diagnosing CPP because of the insurmountable drawbacks of the nonphysiological GnRH stimulation test, which does not truly reflect the level of gonadal development and requires multiple blood samples. Huynh [7] simplified the procedure of the GnRH stimulation test, reducing the duration and number of blood collections, however, it still used the method of stimulation test. Given that the GnRH stimulation test is cumbersome to perform and that overdiagnosis of CPP due to false positives after the GnRH stimulation test has been documented in the infant population [8], the possibility of replacing this test with a simplified evaluation panel including basal laboratory hormonal values, such as LH, and pelvic ultrasonography, which is noninvasive and relatively easy to perform, has been continuously reviewed over the years.

Jung Yu [9] believed the uterine volume of at least 1.07 cm3 was the most predictive parameter among pelvic ultrasonographic findings to diagnose CPP. Pelvic ultrasound indices overlap more in children with PT and precocious puberty and therefore do not have high value for predicting CPP [10], 11]. It has been mentioned in the literature that basal gonadotropin levels are useful, but different studies have different cutoff values for diagnosing CPP. e.g. Yu Ding [12] believed the appropriate cutoff value of basal LH levels associated with a positive response of the GnRH stimulation test was 0.35 IU/L, with a sensitivity of 63.96 % and specificity of 76.3 % from the ROC curves when Youden’s index showed the maximum value. However, Li xue [13] believed at a baseline LH level of 0.45 IU/L, the Youden index reached the peak value, and the sensitivity and specificity were 66.7 and 80 %, respectively, for the diagnosis of CPP. So the ideal cutoff value for diagnosing CPP is difficult to determine. Zou P et al. [14] used pituitary MRI as an indicator for the diagnosis of precocious puberty. They determined the activation status of the HPG axis based on pituitary size and volume, which has some theoretical significance. However, due to the small size of the pituitary gland itself, and its division into the anterior lobe, posterior lobe, and stalk, it is difficult to assess subtle changes in different regions for the evaluation of sexual development. This increases the workload for radiologists and clinicians. The younger the age, the higher the probability of abnormal cranial imaging. Meta analysis shows that 6.3 % of girls and 16.3 %–38.0 % of boys with CPP have intracranial lesions [15], 16]. Therefore, the guideline [1]recommend that all boys and girls under 6 years old diagnosed with CPP should undergo cranial magnetic resonance imaging to exclude intracranial lesions; When CPP girls over 6 years old show signs of rapid sexual development or neurological and psychiatric abnormalities, they should also consider undergoing cranial imaging examination. The pituitary MRI is not necessary for girls with early breast development after the age of 6, which can lead to unnecessary examinations and economic burden. Jingyu You et al. [17] used the age of onset of sexual development (breast development) as a predictive indicator, however, the age of sexual development initiation is often difficult for many parents and patients to recall accurately, leading to recall bias. Bo Yuan et al. [18] used the initial diagnosis age, baseline gonadotropin levels, and pelvic ultrasound indices to predict the diagnosis of CPP, without using bone age indicators, however, bone age is of great significance in the process of sexual precocity. Using more comprehensive indicators for evaluation will lead to better predictive results.

As early as the 1970s, Frisch [6] proposed the “critical weight hypothesis”, which stated that a certain body fat depot seems to be required for the process of initiating normal reproductive function. Several studies and epidemiological reports have noted that obesity in girls is a risk factor for early pubertal development [19], [20], [21]. Research in females suggests that obesity is more likely to lead to precocious puberty [22], 23]. We similarly found in a previous study [2], the physical development, including height, weight and BMI measurements, of girls with early breast development, compared with that of normally developing girls, was significantly advanced corresponding to the mean values for girls older by 1–2 year, finding consistent with reports of other studies [24], [25], [26]. Girls in the PD group had higher weight, height, and BMI measurements than those in the PT group.

We focused on physical signs and a combination of biomarkers for diagnosing CPP. In this study, we developed a disease diagnostic model to predict a patient’s risk of diagnosing central precocious puberty, and other methods of machine learning models are worth our reference and learning [27], [28], [29]. The AUCs of the development and validation queues for this model are relatively high, and they maintain a high level of consistency, indicating that this disease diagnostic model is stable and reliable. The model can be used by clinicians to estimate an girl with breast development, whose risk of developing CPP. The seven variables in this disease model, are routinely monitored in outpatient visits, making them easily obtainable and comparatively objective. This does not add to the burden of doctors’ diagnosis and treatment or the financial burden of parents. If the estimated risk of CPP in the patient is low, clinical doctors can choose to follow up and monitor, reducing anxiety for both parents and the patient. If the assessment results indicate a high probability of CPP, after considering the potential consequences of complete grading precocity, the choices are active treatment or monitoring. It is not necessary for every girl with breast development to undergo GnRH stimulation testing. However, if a girl with early breast development is considered to have a lower probability of precocious puberty through this disease diagnosis model, but the clinical manifestations of the child support precocious puberty, it is necessary to further conduct GnRH stimulation test to avoiding misdiagnosis.

Limitations

The current investigation has certain constraints, notably the employment of a narrow sample population when developing the model. Additionally, the data utilized for this research were exclusively sourced from China, potentially limiting the model’s universality across different global locations. It is imperative to gather additional data from diverse regions outside of China to substantiate the model’s efficacy.

Conclusions

The research involved crafting a predictive algorithm designed to evaluate the likelihood of precocious puberty in young females exhibiting breast growth. This disease diagnostic model relies on seven frequently recorded clinical parameters during standard clinic appointments. By predicting the probability of CPP, the tool aids in distinguishing between patients who may or may not have CPP, thus facilitating the choice of suitable therapeutic interventions and preventing unnecessary diagnoses and misdiagnosis.


Corresponding author: Prof. Chun-Xiu Gong, Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China, E-mail:

Funding source: Beijing Municipal Science & Technology Commission

Award Identifier / Grant number: Z201100005520061

Acknowledgments

The study was supported by the patients and the cooperation of their families and the help of doctors and nurses in the Department of Endocrinology.

  1. Research ethics: The study protocol conformed to the ethical guidelines of the Declaration of Helsinki. The study was approved by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University (No.2020-k-180).

  2. Informed consent: Due to the retrospective nature of the study, committees of Beijing Children’s Hospital waived the need of obtaining informed consent.

  3. Author contributions: All the authors helped to perform the research; Manman Zhao and Yannan Zheng collected clinical samples and wrote the manuscript; Guoshuang Feng performed statistical analysis; Bingyan Cao contributed to the project management; Chunxiu Gong conceived and designed the project and revised the manuscript. All the listed authors revised the paper critically and approved the final version of the submitted manuscript.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: Supported by Beijing Municipal Science & Technology Commission. No. Z201100005520061.

  7. Data availability: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

1. The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of PediatricsEditorial Board, Chinese Journal of Pediatrics. Expert consensus on the diagnosis and treatment of central precocious puberty (2022). Chin J Pediatr 2023;61:16–22. https://doi.org/10.3760/cma.j.cn112140-20220802-00693.Search in Google Scholar PubMed

2. Zhao, M, Liu, M, Cao, B, Gong, C. Associations between body mass index and pubertal development based on the outcomes of girls with early breast development. Front Endocrinol 2022;21:13–23. https://doi.org/10.3389/fendo.2022.991908.Search in Google Scholar PubMed PubMed Central

3. Lebrethon, MC, Bourguignon, JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 2000;12:394–9. https://doi.org/10.1097/00008480-200008000-00020.Search in Google Scholar PubMed

4. Mul, D, Oostdijk, W, Drop, SL. Early puberty in girls. Best Pract Res Clin Endocrinol Metabol 2002;16:153–63. https://doi.org/10.1053/beem.2001.0187.Search in Google Scholar PubMed

5. Wilkins, L. The diagnosis and treatment of endocrine disorders of childhood and adolescence. Springfield, IL: Charles C Thomas; 1956.Search in Google Scholar

6. Frisch, RE, McArthur, JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 1974;185:949–51. https://doi.org/10.1126/science.185.4155.949.Search in Google Scholar PubMed

7. Huynh, QTV, Khanh Le, NQ, Huang, S-Y, Ho, BT, Vu, TH, Pham, HTM, et al.. Development and validation of clinical diagnostic model for girls with central precocious puberty: machine-learning approaches. PLoS One 2022;17:e0261965. https://doi.org/10.1371/journal.pone.0261965.Search in Google Scholar PubMed PubMed Central

8. Bizzarri, C, Spadoniv, G, Bottaro, G, Montanari, G, Giannone, G, Cappa, M, et al.. The response to gonadotropinvreleasing hormone(GnRH) stimulation test does not predict the progression to true precocious puberty in girls with onset of premature thelarche in the first three years of life. J Clin Endocrinol Metab 2014;99:433–9. https://doi.org/10.1210/jc.2013-3292.Search in Google Scholar PubMed

9. Yu, J, Shin, HY, Lee, SH, Kim, YS, Kim, JH. Usefulness of pelvic ultrasonography for the diagnosis of central precocious puberty in girls. Korean J Pediatr 2015;58:294–300. https://doi.org/10.3345/kjp.2015.58.8.294.Search in Google Scholar PubMed PubMed Central

10. Lee, SH, Joo, EY, Lee, JE, Ferreira, BP, Pereira, GA, Borges, MF. The diagnostic value of pelvic ultrasound in girls with central precocious puberty. Chonnam Med J 2016;52:70–4. https://doi.org/10.4068/cmj.2016.52.1.70.Search in Google Scholar PubMed PubMed Central

11. Valverde, ME, Montero, AV, Espí, AG, Munoz, AA. Central or peripheral precocious puberty: diagnostic diffificulties. Indian Pediatr 2016;53:920–2. https://doi.org/10.1007/s13312-016-0961-6.Search in Google Scholar PubMed

12. Ding, Y, Li, J, Yu, YG, Yang, PR, Li, HY, Shen, YN, et al.. Evaluation of basal sex hormone levels for activation of the hypothalamic-pituitary-gonadal axis. J Pediatr Endocrinol Metabol 2018;31:323–9. https://doi.org/10.1515/jpem-2017-0124.Search in Google Scholar PubMed

13. Li, X, Ou, Y, Fan, Y. Diagnostic value of baseline serum luteinizing hormone level for central precocious puberty in girls. Chin J Contemp Pediatr 2017;19:729–33.Search in Google Scholar

14. Zou, PF, Zhang, LF, Zhang, RF, Wang, CY, Lin, XT, Lai, C, et al.. Development and validation of a combined MRI radiomics, imaging and clinical parameter-based machine learning model for identifying idiopathic central precocious puberty in girls. J Magn Reson Imag 2013;58:1977–87. https://doi.org/10.1002/jmri.28709.Search in Google Scholar PubMed

15. Mogensen, SS, Aksglaede, L, Mouritsen, A, Sørensen, K, Main, KM, Gideon, P, et al.. Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty. PLoS One 2012;7:e29829. https://doi.org/10.1371/journal.pone.0029829.Search in Google Scholar PubMed PubMed Central

16. Wang, J, Zhan, S, Yuan, J, Ullah, R, Dong, G, Wu, W, et al.. The incidence of brain lesions in central precocious puberty: the main cause for Chinese boys was idiopathic. Clin Endocrinol 2021;95:303–7. https://doi.org/10.1111/cen.14462.Search in Google Scholar PubMed PubMed Central

17. You, JY, Cheng, XY, Li, XJ, Li, MQ, Yao, L, Luo, FH, et al.. Clinical risk score for central precocious puberty among girls with precocious pubertal development: a cross sectional study. BMC Endocr Disord 2021;21:75–86. https://doi.org/10.1186/s12902-021-00740-7.Search in Google Scholar PubMed PubMed Central

18. Yuan, B, Pi, YL, Zhang, YN, Xing, P, Chong, HM, Zhang, HF. A diagnostic model of idiopathic central precocious puberty based on transrectal pelvic ultrasound and basal gonadotropin levels. J Int Med Res 2020;48:1–7. https://doi.org/10.1177/0300060520935278.Search in Google Scholar PubMed PubMed Central

19. Lee, JM, Appugliese, D, Kaciroti, N, Corwyn, RF, Bradley, RH, Lumeng, JC. Weight status in young girls and the onset of puberty. Pediatrics 2007;119:624–30. https://doi.org/10.1542/peds.2006-2188.Search in Google Scholar PubMed

20. Currie, C, Ahluwalia, N, Godeau, E, Gabhainn, SN, Due, P, Currie, DB. Is obesity at individual and national level associated with lower age at menarche? Evidence from 34 countries in the health behaviour in school-aged children study. J Adolesc Health 2012;50:621–6. https://doi.org/10.1016/j.jadohealth.2011.10.254.Search in Google Scholar PubMed

21. Lazzeri, G, Tosti, C, Pammolli, A, Troiano, G, Vieno, A, Canale, N, et al.. Overweight and lower age at menarche: evidence from the Italian HBSC cross-sectional survey. BMC Wom Health 2018;18:168–75. https://doi.org/10.1186/s12905-018-0659-0.Search in Google Scholar PubMed PubMed Central

22. Crocker, MK, Stern, EA, Sedaka, NM, Shomaker, LB, Brady, SM, Ali, AH, et al.. Sexual dimorphisms in the associations of BMI and body fat with indices of pubertal development in girls and boys. J Clin Endocrinol Metab 2014;99:E1519–29. https://doi.org/10.1210/jc.2014-1384.Search in Google Scholar PubMed PubMed Central

23. Deng, Y, Liang, J, Zong, Y, Yu, P, Xie, R, Guo, YF, et al.. Timing of spermarche and menarche among urban students in Guangzhou, China: trends from 2005 to 2012 and association with Obesity. Sci Rep 2018;8:263–70. https://doi.org/10.1038/s41598-017-18423-6.Search in Google Scholar PubMed PubMed Central

24. Chen, C, Zhang, Y, Sun, W, Chen, Y, Jiang, Y, Song, Y, et al.. Investigating the relationship between precocious puberty and obesity: a cross-sectional study in Shanghai, China. BMJ Open 2017;7:e014004. https://doi.org/10.1136/bmjopen-2016-014004.Search in Google Scholar PubMed PubMed Central

25. Aris, IM, Rifas-Shiman, SL, Zhang, X, Yang, S, Switkowski, K, Fleisch, AF, et al.. Association of BMI with linear growth and pubertal development. Obesity 2019;27:1661–70. https://doi.org/10.1002/oby.22592.Search in Google Scholar PubMed PubMed Central

26. Lai, X, Fu, SM, Lin, JF, Huang, SZ, Yu, TT, Li, XQ, et al.. Association of obesity and body fat percentage with pubertal state in six- to nine-year-old Chinese females. Childood Obes 2021;17:525–33. https://doi.org/10.1089/chi.2020.0247.Search in Google Scholar PubMed

27. Liang, W, Liang, H, Ou, L, Chen, B, Chen, A, Li, C, et al.. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180:1081–9. https://doi.org/10.1001/jamainternmed.2020.2033.Search in Google Scholar PubMed PubMed Central

28. Nguyen, HS, Ho, DKN, Nguyen, NN, Tran, HM, Tam, KW, Le, NQK. Predicting EGFR mutation status in non-small cell lung cancer using artificial intelligence: a systematic review and meta-analysis. Acad Radiol 2024;31:660–83. https://doi.org/10.1016/j.acra.2023.03.040.Search in Google Scholar PubMed

29. Kha, QH, Le, VH, Hung, TNK, Nguyen, NTK, Le, NQK. Development and validation of an explainable machine learning-based prediction model for drug–food interactions from chemical structures. Sensors 2023;23:3962. https://doi.org/10.3390/s23083962.Search in Google Scholar PubMed PubMed Central


Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/jpem-2024-0419).


Received: 2024-08-28
Accepted: 2025-01-03
Published Online: 2025-01-16
Published in Print: 2025-03-26

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Thyroid surgery in pediatric age: a 10-year experience at a single center and literature review
  4. Differentiated thyroid cancer in adolescents – does extent of disease at presentation differ with age?
  5. Evaluation of iodine and selenium level and thyroid functions in patients with cystic fibrosis
  6. Interpreting positive celiac serology in children with new-onset type 1 diabetes
  7. Elastographic evaluation for fatty liver disease in north Indian children and adolescents with type 1 diabetes
  8. Diagnostic value of fasting insulin and insulin-like growth factor-1 levels in girls with central precocious puberty
  9. Clinical outcomes of switching to lonapegsomatropin from somatropin for treatment of pediatric growth hormone deficiency
  10. Development of a disease diagnostic model to predict the occurrence of central precocious puberty of female
  11. Adrenal hypoandrogenism in adolescents with premature ovarian insufficiency
  12. The clinical presentation and genetic diagnosis of Tangier disease in the pediatric age group
  13. Clinical and genetic diagnosis of first cohort of differences of sexual development in the Iranian population
  14. Short Communication
  15. Effect of a GnRH injection on kisspeptin levels in girls with suspected precocious puberty: a randomized-controlled pilot study
  16. Case Reports
  17. Coexistence of phenylketonuria and tyrosinemia type 3: challenges in the dietary management
  18. Acrodermatitis dysmetabolica: lessons from two pediatric cases
  19. Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2024-0419/html?lang=en
Scroll to top button